Categories Earnings, Health Care

Zoetis (NYSE: ZTS): Q4 2019 Earnings Snapshot

— Zoetis Inc. (NYSE: ZTS) reported its fourth-quarter 2019 adjusted earnings of $0.92 per share versus $0.88 expected.

— Revenues grew 7% to $1.7 billion versus $1.64 billion expected. On an operational basis, revenue, excluding the impact of foreign exchange, increased by 9%.

Earnings Update by AlphaStreet

— The US segment revenue rose by 6% as growth in key dermatology portfolio across both the Apoquel and Cytopoint brands drove sales of companion animal products higher by 15%.

— International revenue grew 9% on higher sales across key dermatology portfolio and in certain parasiticides, including Simparica and the Revolution/Stronghold franchise, as well as growth across key markets in Western Europe and in China.

— For full-year 2020, the company expects operational growth of 7% to 9.5% in revenue and 8% to 11% in adjusted net income.

— For the full year 2020, the company expects revenue in the range of $6.65-6.8 billion, EPS of $3.53-3.65 and adjusted EPS of $3.90-4.00. The consensus estimates EPS of $4.01 on revenue of $6.7 billion.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Key highlights from Autodesk (ADSK) Q4 2021 earnings results

Autodesk, Inc. (NASDAQ: ADSK) today reported its fourth quarter financial results for the period ended January 31, 2021. Net income for the fourth quarter was $911.3 million, or $4.10 per

Infographic: Beyond Meat (BYND) reports wider Q4 loss; Revenue up 4%

Beyond Meat (NASDAQ: BYND), a specialist in plant-based meat substitutes, Thursday reported a wider loss for the fourth quarter, despite an increase in revenues. The numbers also missed the consensus

Virgin Galactic stock tanks on delayed test flight

Virgin Galactic (NYSE: SPCE) reported fourth-quarter 2020 financial results after the regular market hours on Thursday. The space tourism company reported zero revenue in the fourth quarter, compared to $529,000

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top